Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
This study will evaluate the safety and efficacy of AXS-05 in a randomized, double-blind, active-controlled study in patients diagnosed with major depressive disorder (MDD) experiencing an acute episode.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently meets DSM-5 criteria for MDD
Body mass index (BMI) between 18 and 40 kg/m\^2, inclusive
Agree to use adequate method of contraception for the duration of the study
Additional criteria may apply
You may not be if
Suicide risk
History of treatment resistance in current depressive episode
History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months
Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Additional criteria may apply
Clareo Health | Assessing Symptomatic Clinical Episodes in Depression
